Stay updated with breaking news from Mark Litzow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Study in ASH Late-Breaking Abstracts session: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis.
Phase III study showed 58% reduction in the risk of death versus chemo alone